Johnson & Johnson (NYSE: JNJ) Q3 2020 earnings call dated Oct. 13, 2020

Johnson & Johnson (NYSE: JNJ) reported third-quarter 2020 financial results before the opening bell on Tuesday. The pharmaceutical giant reported a 2% increase in Q3 revenues to $21.1 billion, beating the Wall Street consensus. Earnings of $2.20 per share were also stronger than what analysts had anticipated.

JNJ shares were down 1.6% immediately following the announcement. The stock has gained 4% since the beginning of this year.

Corporate Participants: Christopher DelOrefice — Vice President of Investor Relations

Joseph J. Wolk — Executive Vice President and Chief Financial Officer

Jennifer Taubert — Executive Vice President and Worldwide Chairman – Pharmaceuticals

Ashley McEvoy — Executive Vice President, Worldwide Chairman, Medical Devices

Thibaut Mongon — Executive Vice President, Worldwide Chairman, Consumer Health

Mathai Mammen — Global Head of Janssen Research and Development

Analysts: David Lewis — Morgan Stanley — Analyst

Chris Schott — J.P. Morgan — Analyst

Larry Biegelsen — Wells Fargo — Analyst

Josh Jennings — Cowen & Company — Analyst

Danielle-Antalffy — SVB Leerink — Analyst

Terence Flynn — Goldman Sachs — Analyst

Louise Chen — Cantor Fitzgerald — Analyst

---

Send in a voice message: https://anchor.fm/earningspodcast/message Support this podcast: https://anchor.fm/earningspodcast/support